Riskpilot← Back to searchSign inGet full accessBio Evaluation BO AB
ABActiveOrg 5567064745Engineering activities and related technical consultancy · NACE 7112Est. 20060 employees
Revenue 2025
—
EBITDA margin
—
+23% vs 2024
Equity ratio
81.2%
Financial strength
Net profit 2025
SEK -6K
+76% vs 2024
| Revenue | — | — |
| EBITDA | SEK -22K | +23% |
| Net profit | SEK -6K | +76% |
| Total assets | SEK 3M | +0% |
| Equity | SEK 2,4M | +0% |
| Employees | 0 | — |
Legal name
Bio Evaluation BO AB
Org number
5567064745
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
28 juni 2006
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva varumärkes-, affärs-, organisations- och produktutveckling inom biotek-, speciellt inom biomedicin samt affärsutveckling och utbildning inom vin och vinprovning ävensom idka därmed förenlig verksamhet.
Address
Email
jan-gunnar.gustafsson@bio-consulting.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — |
| Staff expenses | — | — | — | — | — |
| EBITDA | −42 | −36 | −24 | −29 | −22 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −42 | −36 | −24 | −29 | −22 |
| Net financials | — | — | −20 | 6 | 17 |
| Profit before tax | −42 | −36 | −43 | −23 | −6 |
| Tax | −0 | — | — | — | — |
| Net profit | −42 | −36 | −43 | −23 | −6 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 254 | 2 977 | 2 962 | 2 971 | 2 985 |
| Equity | 3 244 | 2 497 | 2 454 | 2 431 | 2 425 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 10 | 480 | 508 | 540 | 560 |
| Total debt | 10 | 480 | 508 | 540 | 560 |
EBITDA margin
-2246200.0%
This company
15.8%
Market median
-14216556% vs market
20212025
Equity ratio
81.2%
This company
38.2%
Market median
+113% vs market
20212025
Return on equity
-0.2%
This company
18.4%
Market median
-101% vs market
20212025
Net profit margin
-553200.0%
This company
8.1%
Market median
-6829730% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Former (1) | ||
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bio Evaluation BO AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sture Jan-Gunnar Gustafsson | Board of Directors | 0 companies |
| Astrid Katarina Strålenhielm | Deputy Board Member | 0 companies |
| Anna Maria Strålenhielm | Board of Directors | 0 companies |